The global prevalence of psoriasis is 2%-3%. The prevalence in Western countries falls between 2% and 4%, while it is relatively lower in Asia, ranging from only 0.1% to 0.5%. In the Chinese population, the prevalence of psoriasis is approximately 0.88%, and the incidence is approximately 0.74%. From 2023 to 2024, significant progress has been achieved across multiple aspects of diagnosis and treatment of psoriasis. In terms of diagnosis, international guidelines have further standardized the criteria for assessing disease severity. Diagnostic criteria for pustular psoriasis have been continuously improved, and the concept of disease modification has been gradually established, providing directions for achieving long-term management goals. The application of artificial intelligence (AI) and digital technologies in assisted diagnosis has become increasingly widespread, promoting the clinical translation of new tools such as automatic lesion recognition, prediction of psoriasis area and severity index (PASI) score, and remote assessment. Regarding comorbidity management, the research focus has shifted from single screening to multi-system coordinated intervention, especially in terms of metabolic abnormalities, cardiovascular risk, and mental health, thereby strengthening the patient-centered comprehensive management concept. Treatment strategies have been continuously updated, with real-world evidence for interleukin (IL)-17 and IL-23 pathway-targeting drugs accumulating. Meanwhile, small molecule drugs such as Janus kinase (JAK) inhibitors and tyrosine kinase 2 (TYK2) inhibitors have demonstrated good efficacy and safety in clinical application. In the future, psoriasis management is expected to transition from short-term control to long-term disease modification. Precision diagnosis, individualized treatment, and multidimensional comorbidity management will be accelerated through AI and omics technologies, facilitating the establishment of a full-cycle, comprehensive psoriasis diagnosis and treatment system.